{"product_id":"disordered-pharmaceutical-materials-9783527331253","title":"Disordered Pharmaceutical Materials","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eA one-stop resource for researchers, developers, and post graduate students in pharmaceutical science. This handbook and ready reference provides detailed, but not overloaded information -- presenting the topic without unnecessarily complex formalism.\u003cbr\u003e As such, it gives a systematic and coherent overview of disordered materials for pharmaceutical applications, covering fundamental aspects, as well as preparation and characterization techniques for the target-oriented development of drug delivery systems based on disordered crystals and amorphous solids. Special attention is paid to examine the different facets and levels of disorder in their structural and dynamic aspects as well as the effect of disorder on dissolution and stability. Chapters on processing induced disorder and on patenting issues round off the book. As a result the book helps overcoming the challenges of using these materials in the pharmaceutical industry.\u003cbr\u003e For pharmaceutical and medicinal chemists, materials scientists, clinical physicists, and pharmaceutical laboratories looking to make better and more potent pharmaceuticals.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1 Some Facets of Molecular Disorder in Crystalline and Amorphous Pharmaceuticals 1\u003cbr\u003e Marc Descamps and Jean-François Willart\u003cbr\u003e 1.1 The Crystal\/Amorph Alternative 2\u003cbr\u003e 1.2 Characteristics of the Disorder in Glass Formers 28\u003cbr\u003e Acknowledgments 51\u003cbr\u003e References 51\u003cbr\u003e 2 Influence of Disorder on Dissolution 57\u003cbr\u003e Khushboo Kothari and Raj Suryanarayanan\u003cbr\u003e 2.1 Introduction 57\u003cbr\u003e 2.2 Approaches to Enhance Solubility 59\u003cbr\u003e 2.3 Measuring the Solubility Advantage of Amorphous Compounds 64\u003cbr\u003e 2.4 Solid Dispersions 66\u003cbr\u003e 2.5 Polymer Properties 67\u003cbr\u003e 2.6 Drug?Polymer Interactions 70\u003cbr\u003e 2.7 Polymer Concentration 71\u003cbr\u003e 2.8 Other Formulation Components 73\u003cbr\u003e 2.9 Formulation Variables 74\u003cbr\u003e 2.10 Reliable Measurement of Supersaturation 75\u003cbr\u003e 2.11 Conclusion 76\u003cbr\u003e References 77\u003cbr\u003e 3 Crystal Imperfections in Molecular Crystals: Physical and Chemical Consequences 85\u003cbr\u003e William Jones and Mark D. Eddleston\u003cbr\u003e 3.1 Introduction 85\u003cbr\u003e 3.2 General Aspects of Defects in Crystals 87\u003cbr\u003e 3.3 Role of Imperfections in Reactivity and Stability ? Chemistry in the\u003cbr\u003e Perfect and Imperfect Lattice 92\u003cbr\u003e 3.4 Role in Physical Processes 96\u003cbr\u003e 3.5 Concluding Remarks 99\u003cbr\u003e References 99\u003cbr\u003e 4 Observation and Characterization of Crystal Defects in Pharmaceutical Solids 103\u003cbr\u003e Mark D. Eddleston andWilliam Jones\u003cbr\u003e 4.1 Introduction 103\u003cbr\u003e 4.2 Techniques for Characterizing Defects within Crystals 104\u003cbr\u003e 4.3 Techniques for Characterizing Defects Emergent at Crystal Surfaces 119\u003cbr\u003e 4.4 Techniques for Quantifying Defect Densities within Crystals 125\u003cbr\u003e 4.5 The Complementarity of Techniques for Characterizing Defects 126\u003cbr\u003e 4.6 Summary and Outlook 127\u003cbr\u003e Acknowledgment 128\u003cbr\u003e References 128\u003cbr\u003e 5 \"Enantiomeric Disorder\" Pharmaceutically Oriented 135\u003cbr\u003e Gerard Coquerel and Rui Tamura\u003cbr\u003e 5.1 Introduction 135\u003cbr\u003e 5.2 Introduction and Lexicon of Specific Terms Used among Chiral Molecules and Chiral Molecular Associations 135\u003cbr\u003e 5.3 Restrictions in Symmetry Operations Inside Crystal Lattices with an Enantiomeric Excess Different from Zero 136\u003cbr\u003e 5.4 Impact of Chirality on Phase Diagrams and the Gibbs?Scott Phase Rule 137\u003cbr\u003e 5.5 Competitions between Solid Solutions (Impact of Polymorphism on Solid Solutions) Application: Preferential Enrichment 149\u003cbr\u003e 5.6 Disorder at Level 3 Multiepitaxy between Enantiomers 154\u003cbr\u003e 5.7 Conclusion and Perspectives 156\u003cbr\u003e Acknowledgments 157\u003cbr\u003e References 157\u003cbr\u003e 6 Conformational Disorder and Atropisomerism in Pharmaceutical Compounds 161\u003cbr\u003e Attilio Cesàro, Barbara Bellich, Giovanna Giannini, and Alessandro Maiocchi\u003cbr\u003e 6.1 Premise: Conformational Energy Barriers in FlexibleMolecules 161\u003cbr\u003e 6.2 Conformational Topology and Crystallization of Chain Molecules 162\u003cbr\u003e 6.3 Conformational Polymorphism and Crystallization of Flexible Molecules 165\u003cbr\u003e 6.4 Conformational Flexibility of Ring Molecules: Carbohydrates 170\u003cbr\u003e 6.5 Hindered Conformational Isomerism: Atropisomerism 172\u003cbr\u003e 6.6 Conclusion 178\u003cbr\u003e Acknowledgments 180\u003cbr\u003e References 180\u003cbr\u003e 7 Tautomerism in Drug Delivery 183\u003cbr\u003e Zaneta Wojnarowska and Marian Paluch\u003cbr\u003e 7.1 Broadband Dielectric Spectroscopy as a Powerful Tool for Investigating the Tautomerization Process in Condensed Materials 187\u003cbr\u003e 7.2 Tautomerization Kinetics of Supercooled Pharmaceuticals 190\u003cbr\u003e Acknowledgment 197\u003cbr\u003e References 198\u003cbr\u003e 8 Disorders in Pharmaceutical Polymers 201\u003cbr\u003e Emeline Dudognon and Sheng Qi\u003cbr\u003e 8.1 Polymers Architectures -\u003cbr\u003e Structural Disorders 202\u003cbr\u003e 8.2 Structural States and Phases Transitions 205\u003cbr\u003e 8.3 Dynamic Disorders 213\u003cbr\u003e 8.4 Blends of Polymer and Small Molecules 221\u003cbr\u003e 8.5 Effect of the Structural Properties of Pharmaceutical Polymers on Their Physical Behavior 224\u003cbr\u003e 8.6 Concluding Remarks 234\u003cbr\u003e References 235\u003cbr\u003e 9 Polymer Gels, Hydrogels, and Scaffolds ? An Overview 241\u003cbr\u003e Madeleine Djabourov and Kawthar Bouchemal\u003cbr\u003e 9.1 Introduction 241\u003cbr\u003e 9.2 Gels and Hydrogels 243\u003cbr\u003e 9.3 Scaffolds 268\u003cbr\u003e 9.4 Conclusion 275\u003cbr\u003e References 276\u003cbr\u003e 10 Use of the Pair Distribution Function Analysis in the Context of Pharmaceutical Materials 283\u003cbr\u003e Pierre Bordet and PaulineMartinetto\u003cbr\u003e 10.1 Introduction 283\u003cbr\u003e 10.2 What Is the PDF? 284\u003cbr\u003e 10.3 How to Measure the PDF 288\u003cbr\u003e 10.4 Modeling of the PDF 290\u003cbr\u003e 10.5 Applications of PDF Analysis to Molecular and Pharmaceutical Compounds 292\u003cbr\u003e 10.6 Conclusion 297\u003cbr\u003e Acknowledgments 298\u003cbr\u003e References 298\u003cbr\u003e 11 Application of Broadband Dielectric Spectroscopy to Study Molecular Mobility in Pharmaceutical Systems 301\u003cbr\u003e Katarzyna Grzybowska, Karolina Adrjanowicz, and Marian Paluch\u003cbr\u003e 11.1 Introduction to Broadband Dielectric Spectroscopy 301\u003cbr\u003e 11.2 Molecular Dynamics in Amorphous Pharmaceutical Systems 316\u003cbr\u003e 11.3 Molecular Mobility and Dielectric Response in Partially Ordered Pharmaceutical Systems 346\u003cbr\u003e Acknowledgment 353\u003cbr\u003e References 353\u003cbr\u003e 12 Raman Spectroscopy in Disordered Molecular Compounds: Application to Pharmaceuticals 361\u003cbr\u003e Alain Hedoux\u003cbr\u003e 12.1 Introduction 361\u003cbr\u003e 12.2 Raman Spectroscopy 362\u003cbr\u003e 12.3 Analysis of Molecular Compounds by Raman Spectroscopy 370\u003cbr\u003e 12.4 Conclusion 388\u003cbr\u003e References 388\u003cbr\u003e XII Contents\u003cbr\u003e 13 Study of Disordered Materials by Terahertz Spectroscopy 393\u003cbr\u003e Juraj Sibik and J. Axel Zeitler\u003cbr\u003e 13.1 Introduction 393\u003cbr\u003e 13.2 Exploration of Terahertz Dynamics Prior to THz-TDS 394\u003cbr\u003e 13.3 Response of Supercooled Liquids and Glasses at Terahertz Frequencies 397\u003cbr\u003e 13.4 Terahertz Studies of Disordered Molecular Solids 400\u003cbr\u003e 13.5 Organic Glass-Forming Liquids 404\u003cbr\u003e 13.6 Characterization of Disordered Biological and Pharmaceutical Systems 410\u003cbr\u003e 13.7 Outlook 416\u003cbr\u003e References 418\u003cbr\u003e 14 Study of Disorder by Solid-State NMR Spectroscopy 427\u003cbr\u003e Marco Geppi, Silvia Borsacchi, and Elisa Carignani\u003cbr\u003e 14.1 Introduction 427\u003cbr\u003e 14.2 Basics of Solid-State NMR 428\u003cbr\u003e 14.3 Static Disorder 433\u003cbr\u003e 14.4 Dynamic Disorder 448\u003cbr\u003e 14.5 A Case Study 458\u003cbr\u003e 14.6 Final Remarks and Future Perspectives 462\u003cbr\u003e References 464\u003cbr\u003e 15 Processing-Induced Disorder in Pharmaceutical Materials 467\u003cbr\u003e Sheng Qi\u003cbr\u003e 15.1 Introduction 467\u003cbr\u003e 15.2 Pharmaceutical Processing 468\u003cbr\u003e 15.3 Conclusion 484\u003cbr\u003e References 485\u003cbr\u003e 16 Patenting of Inventions Relating to Solid Forms, with Special Considerations on Disordered Forms 491\u003cbr\u003e Bertrand Gellie\u003cbr\u003e 16.1 Patentability of Disordered Crystals 493\u003cbr\u003e 16.2 Patentability of Co-crystals 496\u003cbr\u003e 16.3 Patentability of Amorphous Forms 500\u003cbr\u003e 16.4 Patenting (Disordered) Nanocrystals 509\u003cbr\u003e 16.5 Conclusions 511\u003cbr\u003e Index 513","brand":"Wiley-VCH Verlag GmbH","offers":[{"title":"Default Title","offer_id":53196947226967,"sku":"9783527331253","price":138.56,"currency_code":"GBP","in_stock":false}],"url":"https:\/\/bookcurl.com\/products\/disordered-pharmaceutical-materials-9783527331253","provider":"Book Curl","version":"1.0","type":"link"}